617 related articles for article (PubMed ID: 30428415)
1. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
He R; Xu B; Ping L; Lv X
Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
5. 3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis.
Chen NY; Lu K; Yuan JM; Li XJ; Gu ZY; Pan CX; Mo DL; Su GF
Bioorg Chem; 2021 Sep; 114():105101. PubMed ID: 34175723
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity.
Li W; Xu F; Shuai W; Sun H; Yao H; Ma C; Xu S; Yao H; Zhu Z; Yang DH; Chen ZS; Xu J
J Med Chem; 2019 Jan; 62(2):993-1013. PubMed ID: 30525584
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells.
Shaik AB; Rao GK; Kumar GB; Patel N; Reddy VS; Khan I; Routhu SR; Kumar CG; Veena I; Chandra Shekar K; Barkume M; Jadhav S; Juvekar A; Kode J; Pal-Bhadra M; Kamal A
Eur J Med Chem; 2017 Oct; 139():305-324. PubMed ID: 28803046
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives.
Guan YF; Liu XJ; Yuan XY; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Li W; Zhang SY
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443487
[TBL] [Abstract][Full Text] [Related]
11. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
[TBL] [Abstract][Full Text] [Related]
12. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
[TBL] [Abstract][Full Text] [Related]
13. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
14. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
15. Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents
Su Q; Xu B; Tian Z; Gong Z
Acta Pharm; 2022 Sep; 72(3):389-402. PubMed ID: 36651540
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.
Ma Y; Yang X; Han H; Wen Z; Yang M; Zhang Y; Fu J; Wang X; Yin T; Lu G; Qi J; Lin H; Wang X; Yang Y
Bioorg Chem; 2021 Jun; 111():104872. PubMed ID: 33838560
[TBL] [Abstract][Full Text] [Related]
17. Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway.
Wang R; Zhang Q; Peng X; Zhou C; Zhong Y; Chen X; Qiu Y; Jin M; Gong M; Kong D
Sci Rep; 2016 May; 6():27071. PubMed ID: 27243769
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and
Alimujiang Y; Maimaiti A; Ablise M; Yang Z; Liu Z; Wang Y; Mutalipu Z; Yan T
Anticancer Agents Med Chem; 2024; 24(6):423-435. PubMed ID: 38204258
[TBL] [Abstract][Full Text] [Related]
19.
Thongsom S; Racha S; Ei ZZ; Petsri K; Aksorn N; Chamni S; Panpuang V; Zou H; Chanvorachote P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674871
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition.
Li SS; Chen JJ; Zhang MM; Wang WX; Zhang WY; Ma C
Eur J Med Chem; 2024 May; 271():116425. PubMed ID: 38636129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]